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Abstract
Exposure to phthalates in utero alters fetal rat testis gene expression and testosterone production, but much remains to be
done to understand the mechanisms underlying the direct action of phthalate within the fetal testis. We aimed to
investigate the direct mechanisms of action of mono-(2-ethylhexyl) phthalate (MEHP) on the rat fetal testis, focusing on
Leydig cell steroidogenesis in particular. We used an in vitro system based on the culture for three days, with or without
MEHP, of rat fetal testes obtained at 14.5 days post-coitum. Exposure to MEHP led to a dose-dependent decrease in
testosterone production. Moreover, the production of 5 alpha-dihydrotestosterone (5a-DHT) (268%) and androstenedione
(254%) was also inhibited by 10 mM MEHP, whereas 17 alpha-hydroxyprogesterone (17a-OHP) production was found to
increase (+41%). Testosterone synthesis was rescued by the addition of androstenedione but not by any of the other
precursors used. Thus, the hormone data suggested that steroidogenesis was blocked at the level of the 17,20 lyase activity
of the P450c17 enzyme (CYP17), converting 17a-OHP to androstenedione. The subsequent gene expression and protein
levels supported this hypothesis. In addition to Cyp17a1, microarray analysis showed that several other genes important for
testes development were affected by MEHP. These genes included those encoding insulin-like factor 3 (INSL3), which is
involved in controlling testicular descent, and Inha, which encodes the alpha subunit of inhibin B. These findings indicate
that under in vitro conditions known to support normal differentiation of the fetal rat testis, the exposure to MEHP directly
inhibits several important Leydig cell factors involved in testis function and that the Cyp17a1 gene is a specific target to
MEHP explaining the MEHP-induced suppression of steroidogenesis observed.
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Introduction
A number of endocrine disruptors (EDs) are known to be anti-
androgenic [1,2]. Several molecules exert their effect by inhibiting
steroid synthesis within a ‘‘masculinization programming window’’
occurring between gestational day 15.5 and 19.5 in the rat [3,4], of
which are some phthalic acid esters widely used as additives in the
manufacture of plastics [5]. Di-(2-ethylhexyl) phthalate (DEHP) is
the most widely used phthalate [6]. Phthalates are of particular
concern because epidemiological evidence suggests that the
prenatal or neonatal exposure of boys to phthalates affects their
masculinization (decreasing anogenital distance, [7]) and endo-
crine parameters [8]. Indeed, high di-n-butyl phthalate (DBP)
and/or DEHP metabolite concentrations have been associated
with low levels of human sex steroid hormones [9,10].
The endocrine disrupting effects of phthalates have been
extensively studied in the rat [2]. In this species, the male offspring
of females exposed to phthalates during pregnancy were found to
display reproductive abnormalities, such as hypospadias, cryptor-
chidism and malformations of the epididymis, vas deferens,
seminal vesicles and prostate [3,11]. These abnormalities are
consistent with the phthalate-induced fetal inhibition of androgen
production demonstrated by the administration of a number of
phthalates during pregnancy in rats [2]. Furthermore, in an assay
based on rat fetal testes in culture between 14.5 and 17.5
gestational days (GD), mono-(2-ethylhexyl) phthalate (MEHP), an
active metabolite of DEHP, was found to inhibit testosterone
production in a direct, time- and dose-dependent manner [12].
Phthalates do not bind the androgen receptor directly [13,14].
Their effects on testosterone biosynthesis in the rat are thought to
result from the inhibition of the expression of a number of
enzymes involved in cholesterol uptake/transport and steroido-
genesis [15,16,17,18]. However, as these studies were performed in
utero, it was not possible (1) to distinguish between direct effects and
indirect effects involving metabolites; (2) to control the concentra-
tions of phthalates actually acting on the fetal testis or (3) to
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exclude the possibility that phthalate-induced impairment of
masculinization resulted from deficiencies in androgen action
downstream from the testis, as opposed to changes in androgen
production by the fetal testis itself.
The aim of the present studies was therefore first to identify the
origin of the MEHP-induced androgen production inhibition,
using an organotypic culture system for rat fetal gonads [19],
which proved its usefulness for studying the direct endocrine
disruptor-induced testicular dysfunction [12,20]. Second, using
this culture system, we aimed to determine whether the direct
exposure of the rat testis to MEHP could induce other effects than
on steroidogenesis and to identify them.
Materials and Methods
Animals and sample collection
Pregnant female Sprague-Dawley rats (from GERHM-Inserm,
Rennes and Elevage Janvier, Le Genest Saint Isle, Laval, France)
were anesthetized by an intraperitoneal injection of 50 mg/kg
sodium pentobarbital (Sigma Chemicals, Saint-Quentin, France)
on GD 14.5. The testes were aseptically removed from male
fetuses under a binocular microscope and immediately explanted
in vitro. Investigations were conducted according to the guiding
principles for the use and care of laboratory animals and in
compliance with French and European regulations on animal
welfare ( Directive 86/609/CEE; agreement nuC35-238-19).
Culture procedure
Testes were cultured on Millipore filters (pore size: 0.45 mm;
Millipore, Molsheim, France), as previously described [12,19,20].
Briefly, each 14.5 GD fetal testis was placed on a filter floating on
0.5 ml of M199 medium (Invitrogen, Gibco, Eragny, France)
supplemented with gentamicin (50 mg/ml; Life Technologies,
Cergy-Pontoise France) and fungizone (2.5 mg/ml; Life Technol-
ogies, Cergy-Pontoise France) in 24-well tissue culture dishes,
which were then incubated for 72 h at 37uC, under an atmosphere
containing 5% CO2. Explanted testes were cultured with medium
containing 1, 10 or 100 mM MEHP (Interchim SA, Montluc¸on,
France). In a previous study where 10 mM of MEHP were added
to the culture system, only 0.3% of them were present in the
testicular fetal explants [12]; which corresponds to a concentration
of about 2500 mg/L which is relevant to environmental exposures
reported in humans. It is noteworthy that due to the fact that the
culture procedure and analysis are tedious and very time-
consuming, only the dose of 10 mM was selected when 5 alpha-
dihydrotestosterone (DHT) was measured and/or when the origin
of blockade of androgens production was investigated. The doses
of 1 mM and 10 mM of MEHP were chosen for the microarray
experiments. The MEHP stock solutions of 0.1, 1 and 10 mM
were prepared in DMSO (Prolabo, Fontenay-sous-Bois, France),
to give a final concentration of 1/100 (vol/vol) of DMSO in all
conditions. Controls were incubated with 1/100 (vol/vol) DMSO.
Half the volume of the medium was replaced daily, to keep the
MEHP concentration constant. At the end of the culture period,
the whole explant and the medium were frozen separately at
280uC, for further analysis.
Testosterone, 5 alpha-dihydrotestosterone (5a-DHT) and
17 beta-estradiol (17b-E2) assays
After three days of culture, the medium was removed and stored
at 280uC for hormone assays. Testosterone and its metabolites, 5
alpha-dihydrotestosterone (5a-DHT) and 17 beta-estradiol (17b-
E2), were assayed with direct radioimmunoassay (RIA) kits
(Diagnostic System Laboratories Inc., Beckman Coulter, Cergy-
Pontoise, France). Each sample was assayed in duplicate, without
prior extraction. Less than 0.1% cross-reaction with 5a-DHT or
testosterone was observed in the testosterone and 5a-DHT assays,
respectively. In the present assays, the coefficients of variation
were less than 14% for testosterone, 9% for 5a -DHT and 12% for
17b-E2.
17 alpha-hydroxyprogesterone (17a-0HP) and
androstenedione assays
17a-OHP and androstenedione levels were determined by
competitive RIA [21]. Antibodies against 17-hydroxyprogester-
one-3-(CMO)-BSA were obtained from Steranti (St Albans, UK)
and antibodies against androstenedione-11alpha-succinyl-BSA
were obtained from Dr Terqui (INRA, France). Determinations
were carried out directly in 100 ml of culture medium without
prior extraction. Each sample was assayed in duplicate. The
sensitivity was 53 pg/ml for the 17a-OHP assay and 14 pg/ml for
the androstenedione assay. Less than 1% cross-reaction was
observed between testosterone and the antibodies against
androstenedione and 17a-OHP, and about 3% cross-reaction
was observed between progesterone and the antibody against 17a-
OHP. In the present assays, the coefficients of variation were 5.7%
and 6.3% for 17alpha-OHP and androstenedione, respectively.
Supplementation of media with various steroids
precursors during the culture period
In order to specify the enzymatic steps likely to be affected by
MEHP for the synthesis of testosterone, several of its potential
precursors, i.e. pregnenolone, 17a-OHP or androstenedione, were
added at a concentration of 100 ng/ml (about 3.561027 M), in
the presence or absence of MEHP (10 mM). Such levels were 10 to
70-fold higher than those ones reported in blood of adult Sprague-
Dawley male rat [22] and considered as reasonably close to the
physiological endogenous concentrations for in vitro treatments of
implants. After 72 h of culture, concentration values were
determined in the medium for intermediary metabolites, i.e.
17a-OHP and androstenedione, and for testosterone as described
above. The concentrations of ethanol used in our treatments
(maximum 1%) had no effect on the testosterone production of the
controls (n = 10) or testis morphology (data not shown). Finally, the
effect of MEHP on 5alpha-reductase was investigated further by
adding testosterone to the medium at a physiological concentra-
tion of 1027 M in the presence or absence of MEHP (10 mM) and
measuring 5a-DHT levels in the medium after 72 h culture.
RNA labeling for microarray analysis
RNA was labeled with the Agilent Low-Input Linear Amplifi-
cation Labeling Kit, according to the manufacturer’s instructions
(Agilent Technologies, Palo Alto, CA). Briefly, 25 ng of mRNA
from one whole fetal testes treated with MEHP (1 mM or 10 mM)
or from a control testis was used as a template for the synthesis of
cDNA with the T7 primer, MMLV-RT and a master mix cDNA
synthesis buffer containing 16 first strand buffer, 0.1 M
dithiothreitol, 10 mM dNTPs, 1 IU MMLV-RT and 1 IU
RNaseOUT. The MMLV-RT enzyme was inactivated to stop
the reaction and the cDNA synthesis reaction mixture was divided
in two. The cRNAs were labeled with the Agilent low-input
fluorescence labeling kit, in a single cycle of linear amplification,
according to the Agilent method (G414090050). Labeled cRNA
was generated by adding cyanin-3 cytidine triphosphate (CTP)
(Cy3) or cyanin-5 CTP (Cy5), T7 RNA polymerase, and
transcription master mix. Labeling efficiency was checked with
the microarray analysis program on a NanoDrop ND1000
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spectrophotometer (Montchanin, USA), to ensure that only probes
with sufficient Cy3/Cy5 incorporation were hybridized to the
arrays.
Microarray hybridization
Microarray hybridizations were performed with Agilent hybrid-
ization buffers and Agilent Whole Rat Genome 60-mer oligonu-
cleotide arrays, with labeled RNA isolated from whole fetal testis
explant cultures from a single MEHP-treated testes from each of
three different litters compared with a control reference RNA
sample (pooled RNA from 3 DMSO-treated fetal testes from three
different litters) according to the Agilent method (G4140-90050).
The use of a pool of RNA samples from control animals is the
optimal method for detecting changes in gene expression related to
MEHP treatment, because this approach minimizes the error due
to inter-individual biological variation of gene expression in the
control group. Hybridizations were performed in duplicate, to
allow dye swapping. Thus, in one duplicate, the test RNA was
labeled with Cy3 and the reference RNA was labeled with Cy5,
and in the other, the labels were swapped (Cy5-labeled test and
Cy-3-labeled reference RNAs). This duplication was required to
control for the bias towards higher levels of Cy3 incorporation (as
this molecule is smaller than Cy5) when these dyes are included in
labeling reactions. Microarray analysis was performed with whole
fetal testis RNA and Whole Rat Genome 4644K 60mer
oligonucleotide microarray kit (Agilent reference number:
G4131F).
Microarray data analysis and bioinformatics
Genes displaying significant (p,0.01) changes in expression in
response to MEHP exposure were selected by Agilent feature
extraction (v7.1) software, using an Agilent error model (Agilent
Feature Extraction User Manual G2566-90012). Rosetta Resol-
verTM software (Rosetta Biosoftware, Kirkland, USA) was used to
generate ‘‘signature’’ lists of genes displaying significant (p,0.01)
regulation from replicate (n = 6 lots of 3 MEHP-treated testes *
Cy3/cy5 and cy5/cy3) microarray hybridizations, by generating
an error-weighted mean of fold-change (log ratio) values for the
replicates. The ‘‘compare biosets’’ function in ResolverTM was
used to compare signature lists from different fetal testis regions.
Signature gene lists, including GenBank accession numbers and
fold-change values, were also loaded into Ingenuity Pathways
Analysis software for pathway analysis. The microarray data
for this study is MIAME compliant and the raw data has
been deposited in a MIAME compliant database: the NCBI
Geo database (www.ncbi.nih.gov/geo/), under accession number
GSE22218.
Real-time quantitative RT-PCR analysis of gene
expression
Six to 12 testes from the 10 mM MEHP treatment group or
controls were pooled and total RNA was extracted with the
RNeasyH Mini kit (Qiagen, Les Ulis, France) and treated with
DNAse I. Total RNA concentration and integrity were checked
by UV spectrophotometry. First-strand cDNAs were obtained
from 2 mg of total RNA, by reverse transcription for 90 min at
42uC, this reaction being terminated by heating at 94uC for
2 min. Real-time quantitative RT-PCR (qPCR) amplification
was performed in a final volume of 25 ml containing12.5 ml
SYBRH Green qPCR master mix (Applied Biosystems France
SA, Courtaboeuf, France), 1 ml of a 1/5 dilution of cDNA, and
0.5 mM gene-specific forward and reverse primers. The sequences
Figure 1. MEHP inhibits the production of testosterone and 5a-DHT by the fetal testis. Effects of MEHP on the production of testosterone
and 5a-DHT by fetal rat testes cultured for 72 h beginning on GD14.5. Testosterone and 5a-DHT were determined with specific RIAs. Control testes
were cultured in medium containing DMSO, whereas the treated testes were cultured in medium containing 1, 10 or 100 mM MEHP diluted in DMSO.
The testes of different fetuses from different dams were selected at random. Values are means +/2 SEM of 10 testes from the fetuses of 2 litters in 3
independent experiments. The number indicates the percentage decrease relative to the corresponding control. * p,0.05 in Wilcoxon Mann-Whitney
tests comparing treated and control testes in the 5alpha-DHT assay * p,0.05 in non parametric ANOVA for the MEHP dose-response testosterone assay.
doi:10.1371/journal.pone.0027172.g001
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were amplified in duplicate for each sample, in96-well plates,
with the 7500 Real Time PCR sequence detection system
(Applied Biosystems). The amplification protocol was as follows:
initial denaturation and activation at 50uC for 2 min and 95uC
for 10 min, followed by 40 cycles of 95uC for 15 s and 60uC for
1 min. A temperature-determining dissociation step was then
carried out at 95uC for 15 s, 60uC for 15 s and 95uC for 15 s. For
the normalization of cDNA loading, all samples were run in
parallel, with the18S ribosomal protein (18S) gene used as a
reference. Levels of 18S gene expression were similar in control
and phthalate-exposed testes. A standard curve was generated for
each primer pair, from two-fold serial dilutions of a pool of first-
strand cDNA templates from all samples. Standard curves
showed the cycle threshold (Ct) value to be a function of the
logarithm of the number of copies generated, defined arbitrarily
as 1 copy for the standard cDNA pool. The genes involved in
steroidogenesis which were investigated were: Cyp11a1, encoding
the enzyme responsible for converting cholesterol to pregneno-
lone, Hsd3b1, encoding 3-beta-hydroxysteroid dehydrogenase
isomerase 1 (3bHSD), which generates progesterone from
pregnenolone, Cyp17a1, encoding the enzyme with 17a-hydrox-
ylase activity responsible for converting progesterone to 17-
hydroxyprogesterone and 17-hydroxy-progesterone to andro-
stenedione via its 17,20 lyase activity. Furthermore, the gene Star
encoding a key cholesterol transport protein was also assessed.
The forward and reverse primers were as follows:
Star forward-CTGCTAGACCAGCCCATGGAC, Star reverse-
TGATTTCCTTGACATTTGGGTTCC;
Cyp11a1 forward-GGAGGAGATCGTGGACCCTGA, Cyp11a1
reverse-TGGAGGCATGTTGAGCATGG;
Hsd3b1 forward-AGCAAAAAGATGGCCGAGAA, Hsd3b1
reverse-GGCACAAGTATGCAATGTGCC;
Cyp17a1 forward-TGGCTTTCCTGGTGCACAATC, Cyp17a1
reverse-TGAAAGTTGGTGTTCGGCTGAAG;
Protein extraction and western blotting
For protein extraction, we lysed a pool of eight testes per
treatment (MEHP samples vs controls) in RIPA buffer
containing a mixture of protease inhibitors (Sigma), 50 mM
Tris pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate and 0.1% SDS. Total protein extract (20 mg) was
denatured in Laemmli buffer at 95uC and separated by SDS-
PAGE. Proteins were transferred onto PVDF membranes and
stained with Ponceau Red. The membranes were then
hybridized with 1/100 anti-p450c17 (sc-46081), 1/500 anti-
cytochrome b5 (sc-33174) or 1/500 anti-GADPH (sc-25778)
(Santa-Cruz Biotechnology, Heidelberg, Germany) antibodies,
overnight at 4uC. Horseradish peroxidase-conjugated secondary
antibodies (donkey anti-goat, 705-035-147, Jackson ImmunoR-
esearch, Suffolk, UK and donkey anti-rabbit, NA9340V,
Amersham, Les Ulis, France) were added and the membrane
was incubated for 1 hour at room temperature. Antibody
binding was then detected by processing for 2 minutes with
the ECLTM Plus Western Blotting Kit (Amersham). Membranes
were then immediately placed against Kodak Biomax MR film
for 1 to 10 minutes. The films were scanned and the intensity of
the bands was determined with Quantity One software (Biorad,
Marnes la Coquette, France).
Statistical analysis
Wilcoxon Mann-Whitney tests were performed on unpaired
data. For the dose-response experiments, we carried out a non
parametric analysis of variance (ANOVA). We used SAS/STAT
software (version 9.1; SAS institute Inc., Cary, NC, USA) for all
statistical analyses.
Results
MEHP decreases testosterone and 5a-DHT levels
The incubation of fetal testis explants with MEHP resulted in
the dose-dependent inhibition of testosterone production (Fig. 1).
5a-DHT is the principal androgen active in the development of a
number of tissues/organs of the male genital tract [23]. We
therefore determined its concentration in the medium. For the
controls, the concentration of 5a-DHT in the medium was
significantly higher than that of testosterone itself (Fig. 1),
demonstrating that the steroid-5a-reductase enzyme responsible
for converting testosterone to 5a-DHT was active in the explanted
testes over the culture period. MEHP exposure (10 mM) resulted in
markedly lower concentrations of 5a-DHT, indicating that the
phthalate-induced decrease in testosterone levels was unlikely to be
due to an increase in its 5a reduction rate (Fig. 1). 17b-E2
concentrations in the culture medium were also determined, to
investigate the possibility of an MEHP-induced change in the
conversion of testosterone to 17b-E2 by aromatase (P450arom).
However, 17b-E2 levels remained below the detection limit of the
radioimmunoassay (RIA), suggesting that aromatase may be
produced in only small amounts or inactive within the fetal testis
at GD 14.5–17.5 (data not shown).
Figure 2. 17-hydroxyprogesterone (17-OHP) production is
increased whereas androstenedione production is decreased
by exposure of the fetal testes to MEHP. Effects of 10 mMMEHP on
17-OHP and androstenedione secretion by fetal rat testes cultured for
72 h, beginning at GD14.5. We determined 17-OHP and androstenedi-
one concentrations with specific RIAs. Values are means +/2SEM of 8
(17-OHP) and 7 (androstenedione) testes from fetuses of 2 different
litters in 2 independent experiments. The numbers indicate the
percentage decrease or increase relative to the corresponding control.
* p,0.05 and ** p,0.01 in Wilcoxon Mann-Whitney tests comparing
treated and control testes.
doi:10.1371/journal.pone.0027172.g002
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MEHP blocks the conversion of 17 alpha-
hydroxyprogesterone (17a-OHP) to androstenedione
Androstenedione and 17a-OHP concentrations were deter-
mined, for investigation of the D4 steroidogenic pathway [2].
MEHP exerted its inhibitory effects on testosterone production. In
vitro MEHP treatment (10 mM) decreased the concentration of
androstenedione, the immediate upstream D4 steroid precursor of
testosterone, to a similar extent to that of testosterone (253.7% in
MEHP-treated testes versus control testes; p,0.01) (Fig. 2). By
contrast, 17a-OHP, the substrate of 17,20-lyase for androstene-
dione synthesis, accumulated in the medium after MEHP
exposure (+40.9%; p,0.05) (Fig. 2).
For confirmation that MEHP blocked mainly the conversion of
17alpha-OHP to androstenedione, we analyzed 17a-OHP,
androstenedione, testosterone and 5a-DHT concentrations after
three days of culture in medium supplemented with pregnenolone,
17a-OHP, androstenedione or testosterone.
Consistent with the observed blockade of the conversion of 17a-
OHP to androstenedione, pregnenolone supplementation led to a
significant increase in 17a-OHP concentration in both control and
MEHP-treated testes (Fig. 3). Thus, neither 3 beta-hydroxysteroid
deshydrogenase (3b-HSD) nor CYP17 17a-hydroxylase activity
was inhibited by MEHP. Our data also confirmed that the
conversion of 17a-OHP to androstenedione by the 17,20 lyase
activity of CYP17 was indeed inhibited by MEHP, as neither
pregnenolone nor 17a-OHP rescued androstenedione levels in
MEHP-treated testes. By contrast, the supplementation of controls
with these agents caused an increase in androstenedione levels
(Fig. 3). The specificity of CYP17 lyase activity inhibition by
MEHP was further demonstrated by the demonstration that
supplementation with pregnenolone and 17a-OHP did not
increase testosterone synthesis in testes exposed to MEHP.
However, androstenedione supplementation rescued testosterone
production to levels similar to those in control testes (Fig. 3),
indicating that 17 beta- hydroxysteroid deshydrogenase (17b-
HSD) activity was unaffected by MEHP treatment.
Finally, the addition of testosterone to the medium resulted in
an increase in 5a-DHT concentration similar to that observed for
androstenedione-induced testosterone production, indicating that
the steroid-5a-reductase enzyme was highly active in cultured fetal
rat testis and that MEHP did not directly inhibit the production or
activity of this enzyme (Fig. 3).
Direct effects of MEHP on fetal testis gene expression
We then tried to identify the genes most likely to be directly
affected by MEHP. Microarray analysis of MEHP-exposed and
non exposed fetal gonads revealed differential expression of genes
involved in lipid and cholesterol metabolism and transport,
steroidogenesis, redox homeostasis and testis descent and devel-
opment (Table 1).
MEHP (10 mM) treatment also modified the expression patterns
of genes encoding factors important for lipid homeostasis -
apolipoprotein E (APOE), acyl-coenzyme A dehydrogenase
(ACADS) and acyl-coenzyme A oxidase 1 (ACOX1) were
upregulated- whereas genes encoding for cytochrome c (CYCS),
low-density lipoprotein receptor-related protein-associated protein
1 (LRPAP1) and fatty acid-binding protein 3 (FABP3) were
downregulated.
Figure 3. Supplementation of the medium with testosterone and testosterone precursors reveals that only the 17,20 lyase activity
of CYP17 is affected by MEHP treatment. Effect of 3.561027 M pregnenolone (+Pregnenolone), 17-OHP (+17-OHP) androstenedione
(+Androstenedione) or 1027 M testosterone (+Testosterone) in the presence or absence of 10 mM MEHP on 17-OHP, androstenedione, testosterone
and 5a-DHT secretion in vitro. Data are presented relative to the corresponding control (Basal). Values are means +/2SEM of 7 testes from fetuses
taken from 2 litters in 3 independent experiments. * p,0.05 and ** p,0.01 in Wilcoxon Mann-Whitney tests comparing treated and control testes; NS:
not significant.
doi:10.1371/journal.pone.0027172.g003
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At the lowest concentration tested (1 mM), MEHP upregulated
expression of the genes encoding scavenger receptor class B
member 1 (SR-B1) and steroidogenic acute regulatory protein
(STAR), responsible for the entry of cholesterol into Leydig cells
and its transfer to mitochondria, where it is metabolized,
respectively. However, 10 mM MEHP had no significant effect
on these genes. MEHP upregulated the gene encoding for
3hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1)
when added to the medium at a concentration of 1 mM, but
inhibited it at a concentration of 10 mM MEHP. The genes,
encoding farnesyl diphosphate synthase (FDPS) and cytochrome
P450 family 51 (CYP51), which are involved in cholesterol
biosynthesis, were both downregulated by 10 mM MEHP.
Within the group of genes encoding steroidogenic enzymes, only
the expression of Cyp17a1, encoding the 17hydroxylase/17,20-
lyase enzyme responsible for converting progesterone to andro-
stenedione, was significantly inhibited (Table 1), in a concentra-
tion-dependent manner. That expression of Cyp17a1 may be
inhibited by MEHP was confirmed by real-time quantitative RT-
PCR. Other genes encoding proteins involved in steroidogenesis
regulation, such as emopamil-binding protein (sterol isomerase)
(EBP) and ferredoxin 1 (FDX1), were significantly up- and down-
regulated, respectively (Table 1).
Two genes encoding proteins involved in redox homeostasis,
which are important for the regulation of steroidogenic enzyme
activities - glutathione peroxidase 1 (GPX1) and glutathione S-
transferase alpha 4 (GSTA4) - were found to be downregulated in
a dose-dependent manner by MEHP.
Genes involved in testis development for which expression was
modulated by MEHP exposure included those encoding
peroxiredoxin 2 (PRDX2), glutamic-oxaloacetic transaminase 2
(GOT2), FAT tumor suppressor homolog 1 (FAT1), heat shock
protein 90 alpha class A member (HSPCA), inhibin alpha
(INHA), vimentin (VIM), insulin-like factor 3 peptide (INSL3)
and phosphatidylethanolamine-binding protein 1 (PBP). All
these genes were downregulated by MEHP exposure in a dose-
dependent manner. Of particular importance, MEHP affected
the expression of the Insl3 gene, which is known to be expressed
by Leydig cells and is involved in gubernacular ligament
development and testicular descent [24,25]. Of note also is that
the Inha gene, encoding the alpha subunit of Inhibin B and
which is known to be expressed in both Leydig and Sertoli cells
during fetal life [26] was also found to be down-regulated by
MEHP.
For validation of the microarray analysis, RT-PCR was carried
out on a number of genes involved in steroid production and
cholesterol transport. Consistent with the results of microarray
analysis, the Cyp17a1 gene was the only gene encoding a
steroidogenic enzyme displaying lower levels of expression
(232%; p,0.05) in MEHP-exposed testes than in unexposed
organs. Furthermore, the RT-PCR measurements also confirmed
that Star expression in MEHP-treated testes tended to be higher
than in controls (Fig. 4).
MEHP decreases CYP17 protein levels
Consistent with the corresponding levels of mRNA, testis
CYP17 protein concentration was also significantly decreased
(223%; P,0.05) by MEHP treatment, whereas no significant
change was observed for the cytochrome b5 protein (Fig. 5A&B).
Discussion
Changes in the production or action of testosterone are known
to cause a number of disorders, such as hypospadias, cryptorchi-
dism and abnormally low levels of sperm production [1,2,4,27].
Endocrine disruptors (EDs) have received considerable attention
over the last 15 years as they have been experimentally shown to
participate in these disorders, which are increasing in incidence in
humans [28,29,30].
The EDs known to generate these disorders include a number of
antagonists of testosterone action and inhibitors of testosterone
synthesis [1], including the industrial chemicals phthalate esters
[31].
Antiandrogenic effects of DBP and DEHP have been
demonstrated in the rat for doses exceeding 100 to 250 mg/kg/
day administered in utero [2,32,33]. Although essential to the
understanding of the toxicity of phthalates, these experiments have
one limitation is that they do not allow to conclude whether these
effects on the fetal testis were indirect (i.e. via effects on the
Table 1. Genes involved in testicular development and
functions affected in fetal testis explants exposed to MEHP.
Fold-change in expression
Accession number Gene MEHP 1 mM MEHP 10 mM
LIPID METABOLISM AND TRANSPORT
NM_138828 Apoe 1.96** 1.50**
NM_022512 Acads NS 1.33**
NM_017340 Acox1 NS 1.27*
NM_012839 Cycs NS 22.05**
NM_001169113.1 Lrpap1 NS 22.71**
NM_024162 Fabp3 NS 24.87**
CHOLESTEROL METABOLISM AND TRANSPORT
NM_031558 Star 3.46** NS
NM_031541 Scarb1 2.07** NS
NM_017268 Hmgcs1 1.82** 21.48**
NM_031840 Fdps NS 22.86**
NM_012941 Cyp51 NS 22.89**
STEROIDOGENESIS
NM-057137 Ebp 2.92** 2.16**
NM_017126 Fdx1 NS 22.73**
NM_012753 Cyp17a1 22.24** 24.20**
REDOX HOMEOSTASIS
NM_030826 Gpx1 21.24* 22.35**
NM_001106840.1 Gsta4 21.67* 23.10**
TESTIS DESCENT AND DEVELOPMENT
NM_017169 Prdx2 NS 21.75**
NM_013177 Got2 NS 23.30**
NM_031819 Fat1 NS 21.27**
NM_175761 Hspca NS 22.30*
NM_012590 Inha 21.66** 21.80**
NM_031140 Vim 21.26** 22.14*
NM_053680 Insl3 23.55** 22.95**
NM_017236 Pbp 21.58** 24.00**
Fold-change values expressed relative to time-matched untreated controls,
with reciprocal transformation from expression ratios. NS: no significant change
in gene expressions. Values in italics indicate a down-regulation and values in
bold indicate an upregulation.
*p value,0.01 and
**p,0.001.
doi:10.1371/journal.pone.0027172.t001
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mother), direct, or both. In this context, the use of in vitro
approaches is essential.
We recently demonstrated, in an in vitro fetal gonad assay that
MEHP, the bioactive metabolite of DEHP (but not DEHP itself)
inhibited rat Leydig cell testosterone production [12]. This
inhibition of testosterone production (i) occurred in the absence
of any change in Leydig cell number, (ii) was time- and dose-
dependent, (iii) occurred while the fetal testes do not have the
ability to metabolize DEHP or MEHP and (iv) at concentrations
relevant to human exposure [12]. Furthermore this inhibition
appeared to be independent of the other negative effects observed
in the germ cells [12]. The results presented here confirm that
MEHP inhibits testosterone production in our rat fetal gonad
assay and also reveal that 5alpha-DHT production is strongly
decreased as a consequence of testosterone synthesis inhibition.
The complementary approaches used in this study to explore
the origin of the MEHP-induced inhibition of androgen
production by the fetal testis indicated that CYP17/Cyp17a1 was
a target of MEHP. In vivo/in utero, phthalates have been shown to
have broadly inhibitory effects on the expression of genes encoding
steroidogenic enzymes. Thus, in addition to Cyp17a1, the genes
encoding cytochrome P450scc and 3beta-HSD have also been
shown to be inhibited by phthalates [16,17,34,35,36]. The doses of
phthalates used in these experiments may also induce changes
through systemic effects on the pregnant mother or the fetus itself.
Our results clearly indicate that CYP17 is the direct target of
MEHP in fetal rat testes.
We demonstrate that MEHP specifically blocks the 17,20 lyase
activity of CYP17. The two activities of CYP17 (i.e. lyase and
hydroxylase) are regulated by the ratio of hormones to their
substrates [37] and by redox partners.
Our microarray analyses revealed that the genes encoding
oxidative stress proteins such as glutathione peroxidase 1 (GPX1)
and glutathione S-transferase alpha type 4 (GSTA4) were
downregulated by MEHP, possibly as a consequence of testoster-
one inhibition [38]. GPX1 and GSTA are essential for activation
of the 17a-hydroxylase and 17,20 lyase activities of the enzyme
through electrostatic interactions with their cofactors, principally
cytochrome b5 and P450 oxidoreductase (POR) [39]. In contrast
to the reported effects of phthalate exposure in utero [40], the genes
encoding POR and cytochrome b5 were not found here to be
downregulated in fetal testis explants. These findings were
confirmed, for Cyb5a, by RT-PCR (data not shown) and western
blotting. Thus, the phthalate-induced inhibition of CYP17 does
not result from direct inhibition of the interaction of cytochrome
b5 with CYP17. In this study, MEHP decreased expression of the
gene encoding ferredoxin 1 (FDX1), a protein that regulates the
first enzymatic reaction of the steroidogenic pathway, catalyzed by
cytochrome P450scc [41]. Fdx1 was also found to be downregu-
lated by phthalates in utero, potentially accounting, at least in part,
for their anti-androgenic action [17,40]. However, we show here
that the addition of pregnenolone in vitro does not rescue
testosterone levels, suggesting that the effects of MEHP on Fdx1
gene expression are unlikely to be a key element in its effects on
androgen production in vitro.
In contrast to published findings for in utero experiments [15–
18,40], our in vitro assay showed the upregulation of three genes
encoding proteins involved in cholesterol synthesis and transport
the steroidogenic acute regulatory protein (StAR), the hydroxy-3-
methylglutaryl-coenzyme A (HMGCS1), and scavenger receptor
class B isoform 1, (SR-B1) by the lowest concentration (1 mM) of
MEHP used, in fetal testes explants. However, the induction of
Star and Scarb1 gene expression observed with 1 mM MEHP were
not observed with 10 mM MEHP. In 40-day-old rat immature
Leydig cells, Star expression was shown to be inhibited in vitro by a
high dose of MEHP (250 mM) [42]. Accordingly, a recent study
Figure 4. Expression of a number of genes involved in cholesterol transport and steroidogenesis, as determined by real-time
quantitative PCR. 18 S transcript levels were used as a reference, and relative transcript levels were calculated as a fold-change relative to control.
The names of the genes investigated are cytochrome P450, family 17, subfamily A, polypepetide 1 (Cyp17a1), cytochrome P450, family 11, subfamily
A, polypepetide 1 (Cyp11a1), 3 beta- and steroid delta-isomerase 1 (Hsd3b1), Steroidogenic acute regulatory protein (Star). Data are presented as
means 6 SEM for various cDNAs synthesized from the mRNA of 6 to 12 testes from the fetuses of 2 litters in 3 or 4 independent experiments. The
number indicates the percentage decrease relative to the control. * p,0.05 inWilcoxon Mann-Whitney tests comparing treated and control to testes; NS:
not significant.
doi:10.1371/journal.pone.0027172.g004
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has shown that not only Cyp17a1 but also Star expression were
inhibited in MEHP-pretreated mouse Leydig tumor cells MA-10
stimulated by LH [43]. We also observed an increase in the
abundance of mRNA for genes involved in lipid and cholesterol
synthesis, which may regulate testosterone production in rat
Leydig cells: apolipoprotein E (Apoe [44,45]), Acads [46] and the
sterol 8-isomerase (Ebp [47]). As SR-B1, StAR, HMGCS1, APOE
and EBP are all involved at various levels of the steroidogenic
cascade, it is possible that the MEHP-induced stimulation of the
expression of their genes observed here at the lowest dose of
MEHP (1 mM) corresponds to a negative feedback compensation
mechanism counterbalancing the MEHP-induced inhibition of
Cyp17a1 gene expression. The antiandrogen flutamide has been
shown to have similar effects on these genes in rats treated in vivo
[48]. The observed differences between our previous in utero
experiments and this in vitro analysis, particularly in terms of the
expression of the Star and Scarb1 genes, may be accounted for by
the absence of maternal effects of MEHP in this in vitro system
and/or differences in the doses used [12].
Expression of the gene encoding phosphatidylethanolamine-
binding protein 1 (PBP) was inhibited, in a dose-dependent
manner, by MEHP. This may be an indirect consequence of the
MEHP-induced decrease in testosterone production, as Pbp levels
have also been shown to be decreased by castration in the rat [49]
and by exposure to other antiandrogenic agents, such as
prochloraz or flutamide, in castrated rats [50]. The microarray
analysis revealed that expression of a gene encoding the insulin-
like factor 3 peptide (INSL3) and essential for testis positioning was
directly inhibited by MEHP, confirming previous observations
following the administration of DBP and/or DEHP to rats and
mice in vivo [15,17,51] or the exposure of mouse and rat fetal
Leydig cells [52]. Moreover, the gene Inha was inhibited by
MEHP, supporting the hypothesis that this gene is a target of
phthalates, consistent with data from in utero studies [17,40]. The
Inha gene is expressed in both Leydig cells and Sertoli cells, but the
phthalate-induced downregulation of this gene occurs only in
interstitial (Leydig) cells [17]. It was proposed that phthalate
inhibits Inhibin secretion by Leydig cells, thereby modifying
Sertoli cell development [40].
Because an organotypic culture system was used in this study, it
cannot be excluded that the effects observed may not be direct on
Leydig cells but mediated by another/others cell types(s) of the
testis. However, the fact that (i) the deleterious effects of MEHP
chronogically preceded that on germ cells and on Sertoli cells [12],
and that (ii) MEHP-induced suppression of testosterone produc-
tion was observed when isolated Leydig cells and the mouse MA-
10 cells were used [43,53] clearly show that MEHP can directly
target the Leydig cells. Of not also that published data show that
most genes with expression patterns altered by exposure to DBP
exposure in utero are expressed in the interstitial (Leydig cell)
compartment, with considerably fewer of the genes expressed in
the chords (Sertoli and germ cells) being altered [17]. Other
experiments evidenced the rat Leydig cell as being a target to
DEHP after in utero or post-natal exposures [14,27,33]. Here we
demonstrate that MEHP, a widespread endocrine disruptor,
blocks androgen production by specifically targeting the 17,20
lyase activity of CYP17.
In conclusion, our data confirm that several important functions
of the fetal Leydig cells can be altered by MEHP and provide
evidence that its effects result from its direct effects on the fetal
Figure 5. Western blot analysis of P450c17 and Cytochrome b5
protein levels after MEHP exposure. A) Representative Western
blot of protein extracts (20 mg) from a pool of 8 control testes or testes
exposed to 10 mM MEHP. Blots were incubated with anti-p450c17, anti-
Cytochrome b5 and anti-GAPDH antibodies, to control for equal
loading. The apparent molecular masses (kDa) are indicated on the left.
B) Quantification of band intensity on three blots, carried out with
Quantity One software (Biorad). Data are expressed in arbitrary units
relative to the corresponding control. The number indicates the
percentage decrease relative to control. * p,0.05 in Wilcoxon Mann-
Whitney tests comparing treated and control testes. NS: not significant.
doi:10.1371/journal.pone.0027172.g005
Direct Effects of MEHP on Rat Leydig Cells
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27172
testis and that the direct effects of MEHP on the production of
both androgens and INSL3 by Leydig cells must probably
contribute to the dysgenic effects of this phthalate on the
reproductive organs of the male rat and their development.
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